Patient and tumor characteristics: DLBCL newly diagnosed within HMRN, September 2004 to August 2012
| Characteristic . | Study cohort . | Analysis cohort . | |||
|---|---|---|---|---|---|
| Total . | DLBCL NOS . | ||||
| All patients . | R-CHOP treated . | De novo R-CHOP treated . | |||
| All subtypes combined | 2358 (100) | 928 (100) | 839 (100) | 609 (100) | 579 |
| DLBCL NOS | 2170 (92.0) | 839 (90.4) | – | – | – |
| PCNSL | 74 (3.1) | 33 (3.6) | – | – | – |
| Primary mediastinal | 54 (2.3) | 20 (2.2) | – | – | – |
| T-cell/histiocyte-rich | 31 (1.3) | 21 (2.3) | – | – | – |
| Plasmablastic | 24 (1.0) | 14 (1.5) | – | – | – |
| Intravascular | 5 (0.2) | 1 (0.1) | – | – | – |
| Age at diagnosis (range), y | 70.0 (1.6-97.8) | 68.5 (8.5-97.8) | 68.8 (8.5-97.8) | 66.3 (22.8-89.0) | 66.1 (22.8-89.0) |
| Male sex, n (%) | 1231 (52.2) | 500 (53.9) | 451 (53.8) | 326 (53.5) | 309 (53.4) |
| Performance status (ECOG) | |||||
| 0-1 | 1423 (60.3) | 588 (63.4) | 540 (64.4) | 448 (73.6) | 448 (77.4) |
| ≥2 | 680 (28.8) | 256 (27.6) | 219 (26.1) | 120 (19.7) | 120 (20.7) |
| Not known* | 255 (10.8) | 84 (9.1) | 80 (9.5) | 41 (6.7) | 11 (1.9) |
| Stage (Ann Arbor) | |||||
| I | 337 (14.3) | 145 (15.6) | 137 (16.3) | 111 (18.2) | 111 (19.2) |
| II | 383 (16.2) | 161 (17.3) | 149 (17.8) | 139 (22.8) | 139 (24.0) |
| III | 313 (13.3) | 157 (16.9) | 148 (17.6) | 124 (20.4) | 124 (21.4) |
| IV | 900 (38.2) | 321 (34.6) | 269 (32.1) | 184 (30.2) | 184 (31.8) |
| Not fully staged/not known* | 425 (18.0) | 144 (15.5) | 136 (16.2) | 51 (8.4) | 21 (3.6) |
| IPI | |||||
| Low | 445 (20.3) | 213 (23.0) | 192 (22.9) | 178 (29.2) | 178 (30.8) |
| Low/intermediate | 365 (16.7) | 143 (15.4) | 128 (15.3) | 110 (18.1) | 110 (19.0) |
| Intermediate/high | 394 (18.0) | 156 (16.8) | 146 (17.4) | 116 (19.0) | 116 (20.1) |
| High | 462 (19.6) | 167 (18.0) | 150 (17.9) | 95 (15.6) | 95 (16.4) |
| Not known* | 692 (29.3) | 249 (26.8) | 223 (26.6) | 110 (18.1) | 80 (13.8) |
| Cell of origin | |||||
| Classic† | |||||
| GCB | 410 (49.7) | 265 (50.5) | 252 (52.7) | 181 (52.6) | 172 (53.6) |
| ABC | 233 (28.2) | 142 (27.0) | 141 (29.5) | 99 (28.8) | 91 (28.3) |
| Unclassified | 182 (22.1) | 118 (22.5) | 85 (17.8) | 64 (18.6) | 58 (18.1) |
| Refined† | |||||
| GCB | 359 (43.5) | 234 (44.6) | 223 (46.7) | 163 (47.4) | 155 (48.3) |
| ABC | 228 (27.6) | 140 (26.7) | 139 (29.1) | 98 (28.5) | 90 (28.0) |
| MHG | 60 (7.3) | 34 (6.5) | 32 (6.7) | 20 (5.8) | 19 (5.9) |
| Unclassified | 178 (21.6) | 117 (22.3) | 84 (17.6) | 63 (18.3) | 57 (17.8) |
| Treated curatively | 1929 (81.8) | 803 (86.5) | 730 (87.0) | 609 (100.0) | 579 (100.0) |
| R-CHOP treated | 1536 (65.1) | 648 (69.8) | 609 (72.6) | ||
| Median survival (95% CI), y | 4.1 (3.4-4.9) | 6.2 (5.5-7.2) | 6.4 (5.6-7.5) | 10.2 (8.3-11.9) | 10.6 (8.4-12.5) |
| R-CHOP treated (95% CI), y | 9.3 (8.3-10.6) | 10.4 (8.4-12.5) | 10.2 (8.3-11.9) | ||
| 5-y OS (95% CI),% | 47.7 (45.7-49.7) | 54.6 (51.5-57.9) | 55.4 (52.1-58.8) | 67.3 (63.6-71.1) | 68.0 (64.3-71.9) |
| R-CHOP treated (95% CI), % | 62.8 (60.4-65.2) | 67.5 (64.0-71.2) | 67.3 (63.6-71.1) | ||
| Characteristic . | Study cohort . | Analysis cohort . | |||
|---|---|---|---|---|---|
| Total . | DLBCL NOS . | ||||
| All patients . | R-CHOP treated . | De novo R-CHOP treated . | |||
| All subtypes combined | 2358 (100) | 928 (100) | 839 (100) | 609 (100) | 579 |
| DLBCL NOS | 2170 (92.0) | 839 (90.4) | – | – | – |
| PCNSL | 74 (3.1) | 33 (3.6) | – | – | – |
| Primary mediastinal | 54 (2.3) | 20 (2.2) | – | – | – |
| T-cell/histiocyte-rich | 31 (1.3) | 21 (2.3) | – | – | – |
| Plasmablastic | 24 (1.0) | 14 (1.5) | – | – | – |
| Intravascular | 5 (0.2) | 1 (0.1) | – | – | – |
| Age at diagnosis (range), y | 70.0 (1.6-97.8) | 68.5 (8.5-97.8) | 68.8 (8.5-97.8) | 66.3 (22.8-89.0) | 66.1 (22.8-89.0) |
| Male sex, n (%) | 1231 (52.2) | 500 (53.9) | 451 (53.8) | 326 (53.5) | 309 (53.4) |
| Performance status (ECOG) | |||||
| 0-1 | 1423 (60.3) | 588 (63.4) | 540 (64.4) | 448 (73.6) | 448 (77.4) |
| ≥2 | 680 (28.8) | 256 (27.6) | 219 (26.1) | 120 (19.7) | 120 (20.7) |
| Not known* | 255 (10.8) | 84 (9.1) | 80 (9.5) | 41 (6.7) | 11 (1.9) |
| Stage (Ann Arbor) | |||||
| I | 337 (14.3) | 145 (15.6) | 137 (16.3) | 111 (18.2) | 111 (19.2) |
| II | 383 (16.2) | 161 (17.3) | 149 (17.8) | 139 (22.8) | 139 (24.0) |
| III | 313 (13.3) | 157 (16.9) | 148 (17.6) | 124 (20.4) | 124 (21.4) |
| IV | 900 (38.2) | 321 (34.6) | 269 (32.1) | 184 (30.2) | 184 (31.8) |
| Not fully staged/not known* | 425 (18.0) | 144 (15.5) | 136 (16.2) | 51 (8.4) | 21 (3.6) |
| IPI | |||||
| Low | 445 (20.3) | 213 (23.0) | 192 (22.9) | 178 (29.2) | 178 (30.8) |
| Low/intermediate | 365 (16.7) | 143 (15.4) | 128 (15.3) | 110 (18.1) | 110 (19.0) |
| Intermediate/high | 394 (18.0) | 156 (16.8) | 146 (17.4) | 116 (19.0) | 116 (20.1) |
| High | 462 (19.6) | 167 (18.0) | 150 (17.9) | 95 (15.6) | 95 (16.4) |
| Not known* | 692 (29.3) | 249 (26.8) | 223 (26.6) | 110 (18.1) | 80 (13.8) |
| Cell of origin | |||||
| Classic† | |||||
| GCB | 410 (49.7) | 265 (50.5) | 252 (52.7) | 181 (52.6) | 172 (53.6) |
| ABC | 233 (28.2) | 142 (27.0) | 141 (29.5) | 99 (28.8) | 91 (28.3) |
| Unclassified | 182 (22.1) | 118 (22.5) | 85 (17.8) | 64 (18.6) | 58 (18.1) |
| Refined† | |||||
| GCB | 359 (43.5) | 234 (44.6) | 223 (46.7) | 163 (47.4) | 155 (48.3) |
| ABC | 228 (27.6) | 140 (26.7) | 139 (29.1) | 98 (28.5) | 90 (28.0) |
| MHG | 60 (7.3) | 34 (6.5) | 32 (6.7) | 20 (5.8) | 19 (5.9) |
| Unclassified | 178 (21.6) | 117 (22.3) | 84 (17.6) | 63 (18.3) | 57 (17.8) |
| Treated curatively | 1929 (81.8) | 803 (86.5) | 730 (87.0) | 609 (100.0) | 579 (100.0) |
| R-CHOP treated | 1536 (65.1) | 648 (69.8) | 609 (72.6) | ||
| Median survival (95% CI), y | 4.1 (3.4-4.9) | 6.2 (5.5-7.2) | 6.4 (5.6-7.5) | 10.2 (8.3-11.9) | 10.6 (8.4-12.5) |
| R-CHOP treated (95% CI), y | 9.3 (8.3-10.6) | 10.4 (8.4-12.5) | 10.2 (8.3-11.9) | ||
| 5-y OS (95% CI),% | 47.7 (45.7-49.7) | 54.6 (51.5-57.9) | 55.4 (52.1-58.8) | 67.3 (63.6-71.1) | 68.0 (64.3-71.9) |
| R-CHOP treated (95% CI), % | 62.8 (60.4-65.2) | 67.5 (64.0-71.2) | 67.3 (63.6-71.1) | ||
Data are presented as n (%) unless otherwise indicated. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; OS, overall survival.
Includes transformed follicular lymphoma (study cohort, n = 169; analysis cohort, n = 55) where baseline information is taken at the time of first diagnosis but not at transformation.
Percentage of those with material available.